Summary
This study is one single group of participants with non-small cell lung cancer (NSCLC) who
have not been cured by other treatments. It is the first time the drug has been used in
humans. There will be two parts and a sub-study.
The primary purpose of the parts are:
- Dose Escalation: To investigate the safety and tolerability and to determine the maximum
tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a
- Dose Expansion: To investigate the safety and tolerability of DS-1062a in additional
solid tumors
This study is expected to last approximately 6 years from the time the first participant is
enrolled to the time the last subject is off the study. Study sites are located in both the
United States and Japan.
The number of treatment cycles is not fixed in this study. Participants who continue to
benefit from the study treatment may continue, unless:
- they withdraw
- their disease gets worse
- they experience unacceptable side effects.
The primary purpose of the sub-study is to compare the effectiveness of steroid versus
non-steroid mouthwash as prophylaxis against oral mucositis/stomatitis in participants
receiving DS-1062a.
The sub-study is a randomized study that will include approximately 76 participants enrolling
into the Dose Expansion part.